Update from Medscape on the potential treatment "breakthrough" with the anti-malaria treatment HQC (and HQC with azithromycin antibiotic). Experts appear to be divided on this, since the French study by Raoult was open label, but it was controlled with placebo and showed some startling results. Some didn't like that the results were released on YouTube, but this guy Raoult ia a world virology expert, so shouldn't be dismissed.
Larger trials are needed, but for people who are at death's door, I would think they'd start screaming for his drug, if other options haven't worked; in addition, if it can greatly reduce/eliminate the virus, doctors will be screaming for it, so they can get patients out of the ICU. On the flip side, hope is good but false hope is very painful, so let's not celebrate yet, as there have been false starts before on "cures." First of 3 pages of article is reprinted below. Stay tuned.
https://www.medscape.com/viewarticle/927033
Could the old generic
malaria drug hydroxychloroquine (
Plaquenil, Sanofi-Aventis, among others), which is also used for the treatment of rheumatic disease, be an essential treatment for COVID-19?
This hypothesis, put forward by some, including Professor Didier Raoult of the IHU Méditerranée Infection in Marseille, was dismissed by other eminent infectious disease specialists and dismissed as fake news recently by the Ministry of Health.
Yet it resurfaced yesterday with the
presentation on YouTube by Prof Raoult of positive results in a non-randomised, unblinded trial of 24 patients.
This follows encouraging in vitro results obtained by a Chinese team led by Xueting Yao, from Peking University Third Hospital, Beijing, China, which were
published online by the journal
Clinical Infectious Diseases on March 9th. However, the data were deemed insufficient by the infection community to recommend the compound as a treatment.
Moreover,
chloroquine is not listed among the four treatments studied as part of the recently launched European clinical trial piloted by Inserm, which includes 3200 severe hospitalised patients,
including 800 French patients.
Chloroquine was ruled out due to the risk of interactions with other medications for common comorbidities in infected patients, and because of possible adverse effects in patients undergoing resuscitation.
The Marseille Study
The European Union Clinical Trials Register
shows that the Marseille study was accepted on 5th March by the National Medicines Safety Agency (ANSM). It could include up to 25 COVID-19 positive patients, comprising five aged 12–17 years, 10 aged 18–64 years, and 10 more aged 65 years or over.
While the data have not yet been published, and should therefore be interpreted with caution, this non-randomised, unblinded study showed a strong reduction in viral load with hydroxychloroquine.
After 6 days, the percentage of patients testing positive for COVID-19 who received hydroxychloroquine fell to 25% versus 90% for those who did not receive the treatment (a group of untreated COVID-19 patients from Nice and Avignon).
In addition, comparing untreated patients, those receiving hydroxychloroquine and those given hydroxychloroquine plus the antibiotic
azithromycin, the results showed there was "a spectacular reduction in the number of positive cases" with the combination therapy, said Prof Raoult.
At 6 days, among patients given combination therapy, the percentage of cases still carrying SRAS-CoV-2 was no more than 5%.
Azithromycin was added because it is known to be effective against complications from bacterial lung disease but also because it has been shown to be effective in the laboratory against a large number of viruses, the infectious disease specialist explained.
"The aim is not to be right but that our patients get better. No treatment is magic and the publication of the results raises questions but between doing nothing and repositioning drugs based on their adverse effects, interactions, etc, we try things as we go."